ELUTE fiber provides pharmaceutical, therapeutic, and medical device companies with cutting-edge biodegradable polymers for implantable drug delivery.

TissueGen’s patented extrusion process enables delivery of the broadest range of temperature-sensitive pharmaceuticals and biologics previously impossible to incorporate in implantable devices. In more ways than ever, medical device developers can now deploy advanced drug delivery with ELUTE® fiber – an incredible breakthrough that drastically expands the drugs deliverable via implantable fibers.


ELUTE® Fiber


TissueGen’s ELUTE fiber is ideally suited for a broad range of clinical applications and enables drug delivery from implantable devices for many therapeutic indications.

Advanced Drug Delivery


TissueGen’s patented room temperature fiber extrusion technology  preserves the biological activity of incorporated drugs and enables an entirely new format for drug delivery via biodegradable ELUTE fibers.
Learn More

Nerve Regeneration

Nerve Regeneration

ELUTE fiber is driving a paradigm shift in nerve regeneration through controlled, sustained delivery of sensitive biologics including growth  factors from biomimetic three-dimensional structures.
Learn More

Tissue Engineering


Tailored for devices that require both mechanical and pharmaceutical support,  ELUTE fiber is ideal for tissue scaffolds and stents, including TissueGen’s ARCHER™ stent and drug-eluting stent for the biliary, PAD, and DVT markets.
Learn More


TissueGen’s ELUTE fiber has
won the 2015 R&D 100 Award for
Market Disruptor Services Gold!


Upcoming Events

  • MD&M East

    Booth 1570
    June 14-16, 2016,
    New York, NY

Recent Awards


TissueGen’s ELUTE® fiber has won the ITMA Future Materials Award for Most Innovative Small Company!

Latest News

TissueGen Announces ISO13485:2003 Certification and Record Growth Driven by ELUTE® Fiber
Newly Redesigned Website Showcases ELUTE Fiber Applications for Advanced Drug Delivery, Nerve Regeneration and Tissue Engineering Dallas, TX, March 28, 2016 – TissueGen® Inc., developer of ELUTE® fiber, controlled, sustained drug delivery from bioresorbable fiber, has been awarded ISO13485:2003 certification following significant investment in its...
TissueGen’s New ISO Class 7 Facility Supports FDA cGMP Drug Product Manufacturing
Dallas, TX, December 15, 2015 – TissueGen® Inc., developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, today announced the completion of significant facility upgrades now enabling TissueGen to manufacture and develop ELUTE fiber in an ISO Class 7 cleanroom environment...